We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
6 peer-reviewed studies
What the evidence says
Most Dasatinib studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2015–2022 with a typical study size of 14 participants.
Based on 6 studies · 14 total participants
Confidence
LowBy outcome
1 study in the last 5 years
Senolytics improved physical function and increased lifespan in old mice.
Xu, Pirtskhalava, Farr, Weigand, Palmer, Weivoda · Nature medicine (2018)
The Achilles' heel of senescent cells was exploited to identify the first senolytic drugs.
Zhu, Tchkonia, Pirtskhalava, Gower, Ding, Giorgadze · Aging cell (2015)
Senolytic drugs are reviewed from discovery toward clinical translation.
Kirkland, Tchkonia · Journal of internal medicine (2020)
The SToMP-AD pilot trial tested senolytic dasatinib plus quercetin in early Alzheimer's disease.
Gonzales, Garbarino, Marques Zilli, Petersen, Kirkland, Tchkonia · The journal of prevention of Alzheimer's disease (2022)
Senolytics (dasatinib plus quercetin) improved physical function in a first-in-human open-label trial in idiopathic pulmonary fibrosis.
Justice, Nambiar, Tchkonia, LeBrasseur, Pascual, Hashmi · EBioMedicine (2019)
Senolytics decreased senescent cells in humans in a preliminary clinical-trial report.
Hickson, Langhi Prata, Bobart, Evans, Giorgadze, Hashmi · EBioMedicine (2019)